<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01979874</url>
  </required_header>
  <id_info>
    <org_study_id>13-11778</org_study_id>
    <nct_id>NCT01979874</nct_id>
  </id_info>
  <brief_title>The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II</brief_title>
  <acronym>OMEGA-PAD II</acronym>
  <official_title>The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral
      supplementation will improve systemic inflammation, vascular function, and symptomatic status
      of patients with PAD. Investigators will explore novel mechanistic pathways by which n-3 PUFA
      affect PAD, evaluating the role of specialized lipid mediators involved in the resolution of
      inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The OMEGA-PAD II trial will be a 1:1 randomized, double-blinded trial comparing oral
      supplementation of n-3 PUFA (4.4g/day) to placebo in claudicants (Rutherford stage 1-3) for 3
      months. Eligible patients will be screened according to specified inclusion and exclusion
      criteria. All patients will be treated per our current practice as reflected in the American
      Heart Association Practice guidelines on PAD. Blood draws, vascular function testing and
      6-minute walking tests will be performed at baseline and after 3 months. n-3 PUFA
      supplementation will be achieved with 4 capsules of Pro-Omega twice daily (Nordic Naturals,
      Watsonville, California, USA), corresponding to a total of 4.4g/day. Each ProOmega capsule
      contains 325mg of EPA and 225mg of DHA. The placebo group will take the same number of
      capsules containing inactive substance (soybean; Nordic Naturals), designed to be the same
      color and shape as the treatment capsules.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic Inflammatory bio-markers</measure>
    <time_frame>3 months</time_frame>
    <description>reduce circulating pro-inflammatory markers (PIMs) and increase pro-resolution mediators (PRMs) assayed using targeted metabolo-lipidomics, increase PRM production within peripheral circulating monocytes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>3 months</time_frame>
    <description>Will increase brachial artery flow-mediated vasodilation (FMD)and peripheral resistance (AiX) and decrease arterial stiffness in the lower extremities (PWV).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Walking Performance</measure>
    <time_frame>3 months</time_frame>
    <description>Will improve walking distance during 6-minute walk test and improve parameters on the walking impairment questionnaire (WIQ).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Pro-Omega</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pro-Omega</intervention_name>
    <description>Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months</description>
    <arm_group_label>Pro-Omega</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ProOmega Placebo</intervention_name>
    <description>Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Intermittent claudication (Rutherford 1-3)

          2. One of the following:

               1. Resting or exercise ankle-brachial index (ABI) &lt;0.9

               2. toe pressure &lt; 70 mm Hg

               3. documentation on imaging of greater than or equal to 50% stenosis in segments of
                  aortoiliac arteries, femoral arteries, or tibial arteries

          3. Age 50 and more

        Exclusion Criteria:

          1. Critical limb ischemia

          2. Hypersensitivity/allergies to fish or seafood

          3. Already on n-3 PUFA or equivalent

          4. Significant renal, hepatic, and inflammatory disease

          5. Concurrent severe infections

          6. Acute illness (myocardial infarction, stroke, major surgery within 30 days)

          7. Receiving immunosuppressive medications or steroids

          8. Age &lt; 50
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene Grenon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF &amp; SFVAMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Veterans Affairs Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://vascular.surgery.ucsf.edu/research/clinical-research/clinical-trials.aspx</url>
    <description>UCSF &amp; SFVAMC Divisions of Vascular and Endovascular Surgery Clinical Trials</description>
  </link>
  <reference>
    <citation>Grenon SM, Hughes-Fulford M, Rapp J, Conte MS. Polyunsaturated fatty acids and peripheral artery disease. Vasc Med. 2012 Feb;17(1):51-63. doi: 10.1177/1358863X11429175. Review.</citation>
    <PMID>22363018</PMID>
  </reference>
  <reference>
    <citation>Grenon SM, Aguado-Zuniga J, Hatton JP, Owens CD, Conte MS, Hughes-Fulford M. Effects of fatty acids on endothelial cells: inflammation and monocyte adhesion. J Surg Res. 2012 Sep;177(1):e35-43. doi: 10.1016/j.jss.2012.04.010. Epub 2012 Apr 27.</citation>
    <PMID>22572621</PMID>
  </reference>
  <reference>
    <citation>Grenon SM, Conte MS, Nosova E, Alley H, Chong K, Harris WS, Vittinghoff E, Owens CD. Association between n-3 polyunsaturated fatty acid content of red blood cells and inflammatory biomarkers in patients with peripheral artery disease. J Vasc Surg. 2013 Nov;58(5):1283-90. doi: 10.1016/j.jvs.2013.05.024. Epub 2013 Jul 2.</citation>
    <PMID>23830313</PMID>
  </reference>
  <reference>
    <citation>Grenon SM, Owens CD, Alley H, Chong K, Yen PK, Harris W, Hughes-Fulford M, Conte MS. n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial. Vasc Med. 2013 Oct;18(5):263-74. doi: 10.1177/1358863X13503695. Epub 2013 Sep 19.</citation>
    <PMID>24052491</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2013</study_first_submitted>
  <study_first_submitted_qc>November 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2013</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Marlene Grenon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

